3.0.0 3385 2025-01-14T19:03:55Z 2025-01-14T19:03:55Z Senate S S 2023-12-04 118 ssga00 Homeland Security and Governmental Affairs Committee Senate Standing Referred To 2023-12-04T21:34:33Z 2023-12-04 ssga00 Homeland Security and Governmental Affairs Committee Senate Read twice and referred to the Committee on Homeland Security and Governmental Affairs. IntroReferral 2023-12-04 Introduced in Senate IntroReferral 10000 9 Library of Congress H000601 Sen. Hagerty, Bill [R-TN] Bill Hagerty R TN N Government Operations and Politics Congressional oversight 2024-03-21T15:08:31Z Government information and archives 2024-03-21T15:08:31Z Health technology, devices, supplies 2024-03-21T15:08:31Z Public contracts and procurement 2024-03-21T15:08:31Z Government Operations and Politics 2024-02-05T08:00:25Z

00 2023-12-04 Introduced in Senate 2024-02-06T02:19:27Z <p>This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.</p> <p>Specifically, the bill prohibits executive agencies from (1) procuring, obtaining, extending, or renewing a contract to procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern; or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.</p> <p>A <em>biotechnology company of concern</em> includes BGI Group, MGI Group, Complete Genomics, any subsidiary, parent affiliate, or successor of such entities, and any entity that</p> <ul> <li>is subject to the jurisdiction, direction, or control of a foreign adversary;</li> <li>operates primarily in the biotechnology industry; and</li> <li>the Department of Defense (DOD) deems to pose a risk to national security.</li> </ul> <p>DOD must determine, within 90 days after this bill's enactment, whether WuXi AppTec, Axbio, and any subsidiary, affiliate, or successor of such entities, or any other entity headquartered in or organized under the laws of China, is a biotechnology company of concern.</p><p>Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.</p>

Display Title 45 2024-07-24T15:19:30Z Official Title as Introduced 6 2024-02-06T09:08:19Z Introduced in Senate IS Introduced in Senate 2023-12-04T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-118s3385is/xml/BILLS-118s3385is.xml 2023-12-04 Read twice and referred to the Committee on Homeland Security and Governmental Affairs. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.